Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Nazha

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|June 11, 2021
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?Rami Komrokji, Najla Al Ali, Eric Padron, et al.
British Journal of Haematology|March 21, 2019
Impact of germline CTC1 alterations on telomere length in acquired bone marrow failureWenyi Shen, Cassandra M Kerr, Bartlomiej Przychozen, et al.
Haematologica|July 2, 2013
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 monthsAziz Nazha, Hagop Kantarjian, Preetesh Jain, et al.
Leukemia & Lymphoma|January 9, 2019
<i>BCOR</i> and <i>BCORL1</i> mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomesNour Abuhadra, Sudipto Mukherjee, Karam Al-Issa, et al.
Blood|April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesPreetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapyNaval Daver, Theresa Liu Dumlao, Farhad Ravandi, et al.
Journal of Hematology & Oncology|April 11, 2023
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR studyTao Zhang, Paul Auer, Jing Dong, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemiaPaolo Strati, Naval Daver, Farhad Ravandi, et al.
Blood|September 22, 2020
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromesYasunobu Nagata, Ran Zhao, Hassan Awada, et al.
Bone Marrow Transplantation|January 19, 2019
Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromesBetty K Hamilton, Lisa Rybicki, Casandra Hirsch, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|June 11, 2021
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?Rami Komrokji, Najla Al Ali, Eric Padron, et al.
British Journal of Haematology|March 21, 2019
Impact of germline CTC1 alterations on telomere length in acquired bone marrow failureWenyi Shen, Cassandra M Kerr, Bartlomiej Przychozen, et al.
Haematologica|July 2, 2013
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 monthsAziz Nazha, Hagop Kantarjian, Preetesh Jain, et al.
Leukemia & Lymphoma|January 9, 2019
<i>BCOR</i> and <i>BCORL1</i> mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomesNour Abuhadra, Sudipto Mukherjee, Karam Al-Issa, et al.
Blood|April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesPreetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapyNaval Daver, Theresa Liu Dumlao, Farhad Ravandi, et al.
Journal of Hematology & Oncology|April 11, 2023
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR studyTao Zhang, Paul Auer, Jing Dong, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemiaPaolo Strati, Naval Daver, Farhad Ravandi, et al.
Blood|September 22, 2020
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromesYasunobu Nagata, Ran Zhao, Hassan Awada, et al.
Bone Marrow Transplantation|January 19, 2019
Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromesBetty K Hamilton, Lisa Rybicki, Casandra Hirsch, et al.
Pageof 13